Cargando…
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
BACKGROUND: This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembrolizumab in Japanese patients. METHODS: This multicenter,...
Autores principales: | Nishiyama, Hiroyuki, Tanaka, Yu, Hamada, Masahiro, Ozaki, Masahiko, Minegishi, Toshihiko, Ito, Yuichiro, Maekawa, Shinichiroh, Yamamoto, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280973/ https://www.ncbi.nlm.nih.gov/pubmed/37340317 http://dx.doi.org/10.1186/s12885-023-10930-2 |
Ejemplares similares
-
Real‐world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all‐case postmarketing surveillance in Japan
por: Yamazaki, Naoya, et al.
Publicado: (2022) -
Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022) -
Safety and Effectiveness of Molnupiravir (LAGEVRIO(®)) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
por: Kimata, Masahiro, et al.
Publicado: (2023) -
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019) -
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)